uploads/2017/12/Chart-05-1.jpg

Johnson & Johnson’s Pharmaceutical Business Performance in 3Q17

By

Updated

Pharmaceutical business

Johnson & Johnson’s (JNJ) Pharmaceutical business includes the cardiovascular and metabolic products, neuroscience products, immunology products, infectious diseases products, oncology products, and pulmonary hypertension products. The Pharmaceutical business contributed over 49% of the company’s total revenues during 3Q17.

The chart above compares the revenues for the various franchise for the Pharmaceutical segment since 4Q15.

Article continues below advertisement

Cardiovascular and metabolics products

JNJ’s cardiovascular and metabolics products reported revenues of ~$1.6 billion during 3Q17, 3.6% growth compared to 3Q16. The growth in revenues was driven by increased sales of Xarelto and partially impacted by lower sales of Procrit and Invokana.

Neuroscience products

Neuroscience products reported revenues of $1.5 billion during 3Q17 for 2.3% growth compared to 3Q16. The growth in revenues was driven by increased sales of Invega Sustenna and Concerta and partially impacted by lower sales of other neuroscience products.

Article continues below advertisement

Immunology products

Immunology products reported revenues of ~$3. billion during 3Q17 for 6% growth compared to 3Q16. The growth in revenues was driven by increased sales of Stelara and substantially offset by lower sales of other products like Simponi Aria and Remicade.

Infectious disease products

Infectious disease products reported revenues of $813.0 billion during 3Q17, a decrease of 3.4% compared to 3Q16. The decline in revenues was due to the lower sales of Prezcobix and other infectious products and partially impacted by increased sales of Edurant.

Article continues below advertisement

Oncology products

Oncology products reported revenues of $1.9 billion during 3Q17 for 25.1% growth compared to 3Q16. The growth in revenues was driven by increased sales of Darzalex, Imbruvica, and Zytiga and partially offset by lower sales of Velcade.

Pulmonary hypertension products

JNJ’s pulmonary hypertension products were acquired from Actelion in 2Q17 and reported revenues of $670.0 million during 3Q17. Its pulmonary hypertension products include Opsumit, Uptravi, and Tracleer.

The Guggenheim S&P 500 Top 50 ETF (XLG) holds 14.9% of its total investments in healthcare companies. XLG holds 3.3% in Johnson & Johnson (JNJ), 1.9% in Pfizer (PFE), 1.4% in AbbVie (ABBV), and 1.4% in Merck & Co. (MRK).

Advertisement

More From Market Realist